Fiche du document
- doi: 10.1007/s10096-022-04526-0
- issn: 0934-9723
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s10096-022-04526-0
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36376766
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1435-4373
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_5982A68F66EF2
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Pseudomonas pyocyaneaCiter ce document
M. Sadek et al., « Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa. », Serveur académique Lausannois, ID : 10.1007/s10096-022-04526-0
Métriques
Partage / Export
Résumé
We report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P. aeruginosa isolate (P-01) was susceptible to FDC (2 μg/mL), albeit this MIC value was higher than that of a wild-type P. aeruginosa (0.12-0.25 μg/ml). The subsequent isolated strains (P-02, P-03, P-04) displayed increasing levels of FDC MICs (8, 16, and 64 μg/ml, respectively). Those isolates also showed variable and gradual increasing levels of resistance to most β-lactams tested in this study. Surprisingly, no acquired β-lactamase was identified in any of those isolates. Whole-genome sequence analysis suggested that this resistance was driven by multifactorial mechanisms including mutational changes in iron transporter proteins associated with FDC uptake, ampC gene overproduction, and mexAB-oprM overexpression. These findings highlight that a susceptibility testing to FDC must be performed prior to any prescription.